Rawan Almujaydil

Dr. Rawan Almujaydil

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Clinical Oral Implants Research
Verified
Journal Article
Open access
FAFaisal Faihan Alotaibi
Faisal Faihan Alotaibi
JBJacopo Buti
Jacopo Buti
IRIsabella Rocchietta
Isabella Rocchietta
NNNor Shafina Binti Mohamed Nazari
Nor Shafina Binti Mohamed Nazari
RARawan Almujaydil
Rawan Almujaydil
FDFrancesco D'Aiuto
Francesco D'Aiuto
Objectives: To systematically appraise the evidence on premature ridge resorption following various vertical ridge augmentation (VRA) techniques in healthy adult patients undergoing staged VRA procedures. The study aimed to identify VRA techniques resulting in the least premature bone resorption and to rank them using Bayesian Network Meta‐Analysis (NMA). Material and Methods: Searches were conducted in six databases to identify randomised clinical trials (RCT) comparing staged VRA techniques with a minimum of 3 months follow‐up. Relative premature bone resorption (PBR%) overall (primary) and in sites with uneventful versus complicated healing and need for additional bone grafting (NAG) (secondary) were chosen as outcomes. The risk of bias and certainty in evidence were assessed using Cochrane RoB 2.0 and GRADE tools. Bayesian models estimated treatment effects and rankings. Results: Ten RCTs, involving 220 participants and 236 defects, were included. Nine RCTs reported mean PBR%, with a range from 6% to 44%, averaging 26%. Seven treatment groups were evaluated: onlay, onlay + barrier, inlay, guided bone regeneration, distraction osteogenesis (DO), tissue expansion + tunnelling (TET), and cortical tenting. Eight RCTs, involving 160 participants and 176 defects, contributed to the NMA. Compared to onlay, all groups had lower mean PBR%. Inlay had the highest probability of being ranked first (Pr = 0.55), followed by DO (Pr = 0.27) and TET (Pr = 0.15). Healing complications significantly increased PBR% (MD 10%, 95% CrI 4.4–15.7). Conclusion: VRA techniques preserving the periosteum (inlay, DO, and TET) exhibit less PBR compared with other techniques. When techniques involve full flap elevation, clinicians should anticipate volume loss at re‐entry and consider greater grafting volumes to offset PBR. Protocol Registration: PROSPERO ID: CRD42023394396; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=394396

24 May 2025 in Journal of International Medical Research
Verified
Journal Article
Open access
RARawan Almujaydil
Rawan Almujaydil
YYYumeng Yan
Yumeng Yan
SKSandra Kuswandani
Sandra Kuswandani
FAFaisal Alotaibi
Faisal Alotaibi
JSJeanie Suvan
Jeanie Suvan
FDFrancesco D'Aiuto
Francesco D'Aiuto
Aim: To critically assess the evidence on micrografting technology to evaluate its effectiveness when used alone or as an adjunct to regenerative treatment in various medical and dental applications. Methods: Seven electronic databases, including Cochrane Central Register of Controlled Trials (CENTRAL), Medline Ovid, Embase Ovid, Cumulative Index to Nursing and Allied Health Literature EBSCOhost, Web of Science Core Collection, System for Information on Grey Literature in Europe, and Bielefeld Academic Search Engine, were searched until 15 July 2024. Risk of bias assessment and qualitative and quantitative (random-effect models) analyses were conducted. Results: A total of 55 studies were identified. Most studies (n = 24) reported on burns, followed by 10 studies on ulcers/wounds, 7 on androgenetic alopecia, 3 on vitiligo, 3 on cartilage and bone defects, and 1 on coronary artery bypass graft surgery. Dental applications included sinus lift (three studies), socket preservation (two studies), and intrabody defects (two studies). A meta-analysis of four studies on the management of burns confirmed that micrografting led to reduced healing periods compared with other grafting techniques (weighted mean difference: −0.98, 95% confidence interval: −1.84 to −0.12, p = 0.03), with a high level of heterogeneity (83.57%) and risk of bias. Conclusion: Micrografting technology may lead to shorter healing time and improved patient morbidity.

21 October 2026 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
RARawan Almujaydil
Rawan Almujaydil
NLNatalie Leow
Natalie Leow
Linh NguyenLinh Nguyen
Linh Nguyen
WGWilliam V. Giannobile
William V. Giannobile
FDFrancesco D'Aiuto
Francesco D'Aiuto
DKDarnell Kaigler
Darnell Kaigler
Patient-reported outcomes (PROs) are important clinical outcomes, however frequently overlooked. This study assessed PROs and early wound healing following

Verified
Journal Article
Open access
PDF file
RARawan Almujaydil
Rawan Almujaydil
CMC. J. McCann
C. J. McCann
Linh NguyenLinh Nguyen
Linh Nguyen
FDFrancesco D'Aiuto
Francesco D'Aiuto
Despite advances in periodontal regenerative therapies, consistent tissue regeneration remains challenging, with cells playing an essential role in successful repair. Therefore, this study tested different dental bone substitutes embedded in the chorioallantoic membrane (CAM) combined with periosteum-derived micrografts obtained using a chair-side device (Rigenera HBW system). Cell populations within the micrografts were identified and characterised via immunofluorescence and flow cytometry (CD31, CD105, CD34, CD90, CD73, and CD45). A CAM model was employed to examine the angiogenic potential of micrografts combined with bone substitutes, which were analysed through quantitative blood vessel/vascularisation assessments using the Ikosa software (2025), along with histological and immunohistochemical evaluations such as smooth muscle actin (SMA), H&E, and Masson’s trichrome staining. Statistical analysis was performed using GraphPad Prism 10. The addition of periosteum-derived micrografts resulted in angiogenic enhancement compared to the controls. Notable enhancement of total vessel area, total length, and branching points were obtained when Fisiograft® (p = 0.0007, p = 0.0002, and p < 0.0001, respectively), New Shore® (p = 0.0006, p = 0.0149, and p = 0.0083, respectively), and Bio-Oss® (p = 0.0038 and p = 0.0010, respectively) were combined with micrografts, compared to the positive controls. The histological and immunohistochemical analyses confirmed increased vascularisation (positive staining for SMA) in the micrograft groups. Periosteum-derived micrografts represent a promising adjunct to conventional bone-grafting materials, promoting vascularisation and potentially enhancing tissue regeneration and healing outcomes.